Coming Off Blood-Pressure Meds on a GLP-1

As you lose weight on a GLP-1 (Ozempic, Wegovy) or GLP-1/GIP (Mounjaro, Zepbound), your blood pressure usually falls — and for some people that means existing blood-pressure medications become too strong, opening the door to deprescribing (reducing or stopping a BP drug). This isn't speculation: in the STEP 1 and STEP 4 trials, semaglutide lowered systolic and diastolic blood pressure and produced net reductions in antihypertensive medication use versus placebo (Kosiborod 2023 ^[1]); tirzepatide lowered systolic pressure by roughly 4–6 mmHg across doses in meta-analysis (Kanbay 2023 ^[2]). The critical caveat: deprescribing is a clinician-guided process — stopping BP meds on your own, or missing developing low blood pressure, is how people get hurt. Here's what the evidence shows and how it's done safely.

The honest summary

• GLP-1 weight loss lowers blood pressure. Both semaglutide (STEP 1/4, Kosiborod 2023^[1]) and tirzepatide (Kanbay 2023^[2], SBP roughly -4.2 to -5.8 mmHg by dose) significantly reduce blood pressure.
• Medication use actually went down. STEP 1 and 4 showed net reductions in antihypertensive (and lipid-lowering) medication use with semaglutide versus placebo — real-world evidence that some people need less BP medication as they lose weight.
• Deprescribing is a clinician decision, not a DIY one. Reducing or stopping a BP drug requires monitoring (home readings, follow-up) and the right order of withdrawal — it is individualized.
• Watch for symptoms of over-treatment. As your own BP falls, unchanged BP meds can push it too low — dizziness, lightheadedness on standing, fatigue, or fainting are signals to check readings and call your clinician.
• Some BP meds need care during GI side effects. Diuretics, ACE inhibitors, and ARBs interact with dehydration from GLP-1 nausea/vomiting — ask about “sick-day” rules.

What the trials show

Kosiborod 2023^[1] analyzed cardiometabolic risk factors in the STEP 1 and STEP 4 trials of once-weekly semaglutide 2.4 mg in people with overweight or obesity without diabetes. Reductions in systolic and diastolic blood pressure (alongside waist circumference, fasting glucose, fasting insulin, and lipids) were significantly greater with semaglutide than placebo. The standout for this topic: the analysis reported net reductions in antihypertensive and lipid-lowering medication use with semaglutide versus placebo — i.e., on balance, more people were able to step down BP medication. For tirzepatide, Kanbay 2023^[2] (meta-analysis of 7 RCTs) quantified systolic reductions of about -4.2 mmHg at 5 mg up to -5.8 mmHg at 15 mg, dose-dependent. These are meaningful averages — and individuals who lose substantial weight can see larger drops.

Deprescribing — the safe way to do it

“Deprescribing” means intentionally reducing or stopping a medication that's no longer needed (or now too strong). It is a legitimate, often desirable goal as your weight and BP improve — fewer pills, fewer side effects, lower cost. But it has to be done deliberately:

• Don't stop on your own. Abruptly stopping some BP drugs (notably beta-blockers and clonidine) can cause rebound spikes. The order and pace of withdrawal matter.
• Monitor at home. Bring home blood-pressure readings to your clinician — trends guide whether and how to taper.
• Expect a stepwise taper. Clinicians typically reduce one agent at a time, recheck, and adjust — especially as weight loss continues and BP keeps drifting down.
• Flag low-BP symptoms early. Lightheadedness (especially standing up), unusual fatigue, or near-fainting can mean your meds are now too strong for your lower weight.
• Mind the sick-day rules. During GLP-1 GI side effects with dehydration, diuretics/ACE inhibitors/ARBs may need temporary holding — agree on a plan in advance.

What to do with your numbers

• BP trending down, no symptoms: good — share home readings at follow-up; your clinician may start reducing medication as the trend holds.
• Lightheaded, dizzy on standing, or fatigued: check your BP; if it's low, contact your clinician — your meds may need stepping down.
• On a diuretic, ACE inhibitor, or ARB: ask about sick-day holds during GLP-1 GI side effects to protect against dehydration-related problems.
• Already off some BP meds: keep monitoring — as weight stabilizes, your clinician can confirm you still don't need them.

Bottom line

GLP-1 and GLP-1/GIP drugs reliably lower blood pressure, and the trial evidence shows real-world reductions in antihypertensive medication use^[1][2]. For many people, losing weight on these drugs means they can safely come off some BP medication — a genuine win. But deprescribing is a monitored, clinician-led taper, not a self-directed stop, and the flip side (symptomatic low BP from unchanged meds) is just as important to catch. Track your readings and let your prescriber steer.